Melanoma prone families with CDK4 germline mutation: Phenotypic profile and associations with MC1R variants

Journal of Medical Genetics

Volumn 50, Issue 4, 2013, Pages 264-270

  Puntervoll, Hanne Eknes ^a   Yang, Xiaohong R ^b   Vetti, Hildegunn Hoøberg ^c   Bachmann, Ingeborg M ^a,c   Avril, Marie Françoise ^d   Benfodda, Meriem ^e   Catricalá, Caterina ^f   Dalle, Stéphane ^g   Duval Modeste, Anne B ^h   Ghiorzo, Paola ⁱ   Grammatico, Paola ^j   Harland, Mark ^k   Hayward, Nicholas K ^l   Hu, Hui Han ^e   Jouary, Thomas ^m   Martin Denavit, Tanguy ^g   Ozola, Aija ⁿ   Palmer, Jane M ^l   Pastorino, Lorenza ⁱ   Pjanova, Dace ⁿ   Soufir, Nadem ^e   Steine, Solrun J ^a   Stratigos, Alexander J ^o   Thomas, Luc ^g   Tinat, Julie ^h   Tsao, Hensin ^p   Veinalde, Ruta ⁿ   Tucker, Margaret A ^b   Paillerets, Brigitte Bressac de ^q   Newton Bishop, Julia A ^k   Goldstein, Alisa M ^b   Akslen, Lars A ^a,c   Molven, Anders ^a,c   more..

^a UNIVERSITY OF BERGEN   (Norway)

^b NATIONAL CANCER INSTITUTE   (United States)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d université Paris Cité   (France)

^e BICHAT HOSPITAL   (France)

^f SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^g UNIVERSITÉ LYON 1   (France)

^h ROUEN UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY OF GENOA   (Italy)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

^k ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^l QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^m Service de Dermatologie   (France)

ⁿ LATVIAN BIOMEDICAL RESEARCH AND STUDY CENTRE   (Latvia)

^o UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^p MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^q INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CDK4 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; DYSPLASTIC NEVUS; FAMILY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; MALE; MELANOMA; PHENOTYPE; PRIORITY JOURNAL;

ADULT; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; EXONS; FEMALE; GERM-LINE MUTATION; HAIR COLOR; HUMANS; MALE; MELANOMA; MIDDLE AGED; PHENOTYPE; SKIN NEOPLASMS;

EID: 84878886596     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmedgenet-2012-101455     Document Type: Article

References (41)

1. Florell SR, Boucher KM, Garibotti G, Astle J, Kerber R, Mineau G, Wiggins C, Noyes RD, Tsodikov A, Cannon-Albright LA, Zone JJ, Samlowski WE, Leachman SA. Population-based analysis of prognostic factors and survival in familial melanoma. J Clin Oncol 2005;23:7168-77.
2. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH Jr., Tucker MA, Dracopoli NC. Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15-21.
3. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J, McClure M, Aitken JF, Anderson DE, Bergman W, Frants R, Goldgar DE, Green A, MacLennan R, Martin NG, Meyer LJ, Youl P, Zone JJ, Skolnick MH, Cannon-Albright LA. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994;8:23-6.
4. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, Hayward N, Dracopoli NC. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996;12:97-9.
5. Molven A, Grimstvedt MB, Steine SJ, Harland M, Avril MF, Hayward NK, Akslen LA. A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation. Genes Chromosomes Cancer 2005;44:10-8.
6. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
7. Serrano M, Gomez-Lahoz E, DePinho RA, Beach D, Bar-Sagi D. Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science 1995;267:249-52.
8. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998;92:713-23.
9. Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, Azizi E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Albright LA Cannon, Demenais F, Elder DE, Ghiorzo P, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, Mackie RM, Magnusson V, Mann GJ, Niendorf K, Bishop J Newton, Palmer JM, Puig S, Puig-Butille JA, de Snoo FA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 2006;66:9818-28.
10. Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, Fontaine LS, Organic SM, Dracopoli NC, Clark WH Jr., Tucker MA. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995;333:970-4.
11. Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT, Azizi E, Bergman W, Bianchi-Scarra G, Bruno W, Calista D, Albright LA, Chaudru V, Chompret A, Cuellar F, Elder DE, Ghiorzo P, Gillanders EM, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, MacKie RM, Magnusson V, Mann GJ, Bishop JN, Palmer JM, Puig S, Puig-Butille JA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 2007;44:99-106.
12. Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, Stoppa-Lyonnet D, Benard J, Bressac-de Paillerets B. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 1998;7:209-16.
13. Pjanova D, Engele L, Randerson-Moor JA, Harland M, Bishop DT, Bishop JA Newton, Taylor C, Debniak T, Lubinski J, Kleina R, Heisele O. CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population. Melanoma Res 2007;17:185-91.
14. Soufir N, Ollivaud L, Bertrand G, Lacapere JJ, Descamps V, Vitoux D, Lebbe C, Wolkenstein P, Dupin N, Saiag P, Basset-Seguin N, Grandchamp B. A French CDK4-positive melanoma family with a co-inherited EDNRB mutation. J Dermatol Sci 2007;46:61-4.
15. Majore S, De Simone P, Crisi A, Eibenschutz L, Binni F, Antigoni I, De Bernardo C, Catricala C, Grammatico P. CDKN2A/CDK4 molecular study on 155 Italian subjects with familial and/or primary multiple melanoma. Pigment Cell Melanoma Res 2008;21:209-11.
16. Pjanova D, Molven A, Akslen LA, Engele L, Streinerte B, Azarjana K, Heisele O. Identification of a CDK4 R24H mutation-positive melanoma family by analysis of early-onset melanoma patients in Latvia. Melanoma Res 2009;19:119-22.
17. Nikolaou V, Kang X, Stratigos A, Gogas H, Latorre MC, Gabree M, Plaka M, Njauw CN, Kypreou K, Mirmigi I, Stefanaki I, Tsao H. Comprehensive mutational analysis of CDKN2A and CDK4 in Greek patients with cutaneous melanoma. Br J Dermatol 2011;165:1219-22.
18. Ghiorzo P, Bonelli L, Pastorino L, Bruno W, Barile M, Andreotti V, Nasti S, Battistuzzi L, Grosso M, Bianchi-Scarra G, Queirolo P. MC1R variation and melanoma risk in relation to host/clinical and environmental factors in CDKN2A positive and negative melanoma patients. Exp Dermatol 2012;21:718-20.
19. Coleman KG, Wautlet BS, Morrissey D, Mulheron J, Sedman SA, Brinkley P, Price S, Webster KR. Identification of CDK4 sequences involved in cyclin D1 and p16 binding. J Biol Chem 1997;272:18869-74.
20. Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, Bartek J. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996;56:5475-83.
21. Rees JL. The melanocortin 1 receptor (MC1R): more than just red hair. Pigment Cell Res 2000;13:135-40.
22. Mitra D, Luo X, Morgan A, Wang J, Hoang MP, Lo J, Guerrero CR, Lennerz JK, Mihm MC, Wargo JA, Robinson KC, Devi SP, Vanover JC, D'Orazio JA, McMahon M, Bosenberg MW, Haigis KM, Haber DA, Wang Y, Fisher DE. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature 2012;491:449-53.
23. Garcia-Borron JC, Sanchez-Laorden BL, Jimenez-Cervantes C. Melanocortin-1 receptor structure and functional regulation. Pigment Cell Res 2005;18:393-410.
24. Gerstenblith MR, Goldstein AM, Fargnoli MC, Peris K, Landi MT. Comprehensive evaluation of allele frequency differences of MC1R variants across populations. Hum Mutat 2007;28:495-505.
25. Valverde P, Healy E, Jackson I, Rees JL, Thody AJ. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995;11:328-30.
26. Bastiaens M, ter Huurne J, Gruis N, Bergman W, Westendorp R, Vermeer BJ, Bavinck JN Bouwes. The melanocortin-1-receptor gene is the major freckle gene. Hum Mol Genet 2001;10:1701-8.
27. Valverde P, Healy E, Sikkink S, Haldane F, Thody AJ, Carothers A, Jackson IJ, Rees JL. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet 1996;5:1663-6.
28. Palmer JS, Duffy DL, Box NF, Aitken JF, O'Gorman LE, Green AC, Hayward NK, Martin NG, Sturm RA. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype. Am J Hum Genet 2000;66:176-86.
29. Kennedy C, ter Huurne J, Berkhout M, Gruis N, Bastiaens M, Bergman W, Willemze R, Bavinck JN. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 2001;117:294-300.
30. Raimondi S, Sera F, Gandini S, Iodice S, Caini S, Maisonneuve P, Fargnoli MC. MC1R variants, melanoma and red hair color phenotype: a meta-analysis. Int J Cancer 2008;122:2753-60.
31. Goldstein AM, Landi MT, Tsang S, Fraser MC, Munroe DJ, Tucker MA. Association of MC1R variants and risk of melanoma in melanoma-prone families with CDKN2A mutations. Cancer Epidemiol Biomarkers Prev 2005;14:2208-12.
32. Chaudru V, Laud K, Avril MF, Miniere A, Chompret A, Bressac-de Paillerets B, Demenais F. Melanocortin-1 receptor (MC1R) gene variants and dysplastic nevi modify penetrance of CDKN2A mutations in French melanoma-prone pedigrees. Cancer Epidemiol Biomarkers Prev 2005;14:2384-90.
33. Fargnoli MC, Gandini S, Peris K, Maisonneuve P, Raimondi S. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis. Eur J Cancer 2010;46:1413-20.
34. Demenais F, Mohamdi H, Chaudru V, Goldstein AM, Bishop JA Newton, Bishop DT, Kanetsky PA, Hayward NK, Gillanders E, Elder DE, Avril MF, Azizi E, van Belle P, Bergman W, Bianchi-Scarra G, Bressac-de Paillerets B, Calista D, Carrera C, Hansson J, Harland M, Hogg D, Hoiom V, Holland EA, Ingvar C, Landi MT, Lang JM, Mackie RM, Mann GJ, Ming ME, Njauw CJ, Olsson H, Palmer J, Pastorino L, Puig S, Randerson-Moor J, Stark M, Tsao H, Tucker MA, van der Velden P, Yang XR, Gruis N. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. J Natl Cancer Inst 2010;102:1568-83.
35. Goldstein AM, Chaudru V, Ghiorzo P, Badenas C, Malvehy J, Pastorino L, Laud K, Hulley B, Avril MF, Puig-Butille JA, Miniere A, Marti R, Chompret A, Cuellar F, Kolm I, Mila M, Tucker MA, Demenais F, Bianchi-Scarra G, Puig S, de-Paillerets BB. Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from 4 countries. Int J Cancer 2007;121:825-31.
36. Fitzpatrick TB. The validity and practicability of sunreactive subtypes I through VI. Arch Dermatol 1988;124:869-71.
37. Tucker MA, Halpern A, Holly EA, Hartge P, Elder DE, Sagebiel RW, Guerry Dt, Clark WH Jr. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997;277:1439-44.
38. Pastorino L, Bonelli L, Ghiorzo P, Queirolo P, Battistuzzi L, Balleari E, Nasti S, Gargiulo S, Gliori S, Savoia P, Osella S Abate, Bernengo MG, Bianchi G Scarra. CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma. Pigment Cell Melanoma Res 2008;21:700-9.
39. van der Rhee JI, Krijnen P, Gruis NA, de Snoo FA, Vasen HF, Putter H, Kukutsch NA, Bergman W. Clinical and histologic characteristics of malignant melanoma in families with a germline mutation in CDKN2A. J Am Acad Dermatol 2011;65:281-8.
40. Bishop JA, Wachsmuth RC, Harland M, Bataille V, Pinney E, Mac KP, Baglietto L, Cuzick J, Bishop DT. Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations. J Invest Dermatol 2000;114:28-33.
41. de Snoo FA, Hottenga JJ, Gillanders EM, Sandkuijl LA, Jones MP, Bergman W, van der Drift C, van Leeuwen I, van Mourik L, Huurne JA, Frants RR, Willemze R, Breuning MH, Trent JM, Gruis NA. Genome-wide linkage scan for atypical nevi in p16-Leiden melanoma families. Eur J Hum Genet 2008;16:1135-41.